Synopsis : Motilal Oswal has initiated coverage on Emcure Pharmaceuticals with a 'Buy' rating and a target price of ₹2,260, implying over 27% upside. The brokerage expects strong earnings growth driven by its domestic chronic portfolio, international business and strategic partnerships.
Motilal Oswal Financial Services has initiated coverage on Emcure Pharmaceuticals with a 'Buy' rating and a target price of ₹2,260, implying an upside potential of more than 27% from the current market price.
The brokerage believes Emcure is entering a phase of sustained earnings growth, supported by a diversified domestic franchise, expanding international operations, strategic partnerships with global pharmaceutical companies and healthy return ratios.
According to Motilal Oswal, the company has successfully evolved from being a women's healthcare specialist into a diversified pharmaceutical player with growing presence across multiple chronic therapy segments.
Multi-engine growth expected over FY26-FY28
Motilal Oswal described Emcure as a "multi-engine growth story", expecting strong earnings momentum over the next three years.
The brokerage estimates:
- Revenue CAGR of 14%
- EBITDA CAGR of 20%
- Profit After Tax (PAT) CAGR of 28%
between FY26 and FY28.
The growth is expected to be driven by an expanding product portfolio, improved commercial execution and continued traction across both domestic and international markets.
International business remains a key growth driver
Emcure has steadily expanded its overseas presence over the past few years.
According to the brokerage, international markets contributed nearly 56% of FY26 revenue.
Among overseas geographies:
- Canada remains the company's fastest-growing and most profitable international market.
- Europe has significantly outperformed the broader pharmaceutical market, delivering revenue growth around 500 basis points ahead of industry growth between FY23 and FY26.
Motilal Oswal believes this diversified global presence provides greater earnings stability while reducing dependence on any single geography.
Strong domestic leadership in chronic therapies
While Emcure continues to hold a leadership position in women's healthcare, the company has significantly broadened its domestic portfolio.
The brokerage highlighted the company's expansion across:
- Cardiology
- Central Nervous System (CNS)
- Anti-diabetes
- Oncology
- HIV
Emcure currently ranks second in the gynaecology segment and continues to strengthen its domestic franchise through increased field-force expansion and sustained investment in brand building.
Strategic partnerships strengthen specialty portfolio
One of the major positives highlighted by Motilal Oswal is Emcure's asset-light partnership model.
Instead of investing heavily in research across every therapy area, the company has entered collaborations with several global pharmaceutical companies.
Some of the key partnerships include:
- Sanofi for cardiovascular therapies
- Novo Nordisk for diabetes and obesity treatments, including semaglutide
- Roche for nephrology and transplant therapies
The brokerage believes these collaborations help Emcure expand into high-growth specialty segments while maintaining strong capital efficiency.
Healthy return ratios support valuation
Motilal Oswal expects Emcure to maintain an average Return on Equity (RoE) of around 20% during FY26-FY28.
The brokerage noted that only a handful of healthcare companies under its coverage universe consistently generate similar return ratios.
Based on this, it has assigned the stock a valuation multiple of 28 times FY28 earnings, which forms the basis of its ₹2,260 target price.
Strong share price performance
Emcure Pharmaceuticals has delivered healthy returns across multiple time frames.
The stock has gained:
- Around 9% over the last five trading sessions
- 2.7% during the past month
- Nearly 20% over the last six months
- Around 35.5% over the past one year
The recent rally reflects improving investor confidence following strong financial performance and positive brokerage commentary.
Q4FY26 earnings remain strong
The company reported another healthy quarter during Q4FY26.
Key financial highlights included:
- Net Profit: ₹243 crore, up 29% YoY
- Revenue: ₹2,469.7 crore, up 17% YoY
- EBITDA: ₹479.5 crore, up 19% YoY
- EBITDA Margin: Improved to 19.4% from 19.0% a year earlier
The continued improvement in profitability further strengthens the brokerage's confidence in Emcure's long-term earnings outlook.
Conclusion
Motilal Oswal believes Emcure Pharmaceuticals offers a compelling long-term growth opportunity supported by multiple earnings drivers.
Its leadership in women's healthcare, expanding chronic disease portfolio, growing international franchise, strategic partnerships with global pharmaceutical companies and healthy return ratios position the company well for sustained earnings growth.
The brokerage expects these factors to support strong revenue and profit growth over the next few years and has therefore initiated coverage with a 'Buy' rating and a target price of ₹2,260, implying an upside potential of over 27%.
Disclaimer : The stock recommendation, earnings projections and target price mentioned in this article are based on a research report published by Motilal Oswal Financial Services and are provided solely for informational and educational purposes. They should not be construed as investment advice or a recommendation to buy, sell or hold any security. Investments in equities are subject to market risks, and future returns or target prices are not guaranteed. Investors should conduct their own research and consult a SEBI-registered investment advisor before making any investment decisions.
.jpg)